Skip to main content
Figure 2 | Breast Cancer Research

Figure 2

From: Oestrogen is bad for patients with breast cancer?

Figure 2

Anticipated treatment plan for third-line endocrine therapy. Patients must have responded and failed two successive antihormonal therapies to be eligible for a course of low-dose oestradiol therapy for 3 months. The anticipated response rate is 30% [44] and responding patients will be treated with anastrozole until relapse. Validation of the treatment plan via the Center of Excellence Grant (Figure 1) will establish a platform to enhance response rates with apoptotic oestrogen by integrating known inhibitors of tumour survival pathways into the 3-month low-dose oestrogen debulking treatment plan. The overall goal is to increase response rates and maintain patients for longer on antihormonal strategies before chemotherapy is required.

Back to article page